|
US4873192A
(en)
|
1987-02-17 |
1989-10-10 |
The United States Of America As Represented By The Department Of Health And Human Services |
Process for site specific mutagenesis without phenotypic selection
|
|
NZ227684A
(en)
|
1988-01-30 |
1991-07-26 |
Merck Sharp & Dohme |
Pyrazine, pyridazine, and pyrimidine derivatives and pharmaceutical compositions
|
|
GB9005737D0
(en)
|
1990-03-14 |
1990-05-09 |
Beecham Group Plc |
Novel compounds
|
|
FR2676444B1
(fr)
*
|
1991-05-16 |
1995-03-10 |
Sanofi Elf |
Nouveaux derives d'amino-3 pyridazines actifs sur le systeme nerveux central, procede de preparation et compositions pharmaceutiques en contenant.
|
|
EP1191097A1
(en)
|
2000-09-21 |
2002-03-27 |
Leids Universitair Medisch Centrum |
Induction of exon skipping in eukaryotic cells
|
|
WO2003020952A2
(en)
|
2001-08-31 |
2003-03-13 |
Gen-Probe Incorporated |
Affinity-shifted probes for quantifying analyte polynucleotides
|
|
US7135484B2
(en)
|
2002-08-14 |
2006-11-14 |
Abbott Laboratories |
Azabicyclic compounds are central nervous system active agents
|
|
NZ538512A
(en)
|
2002-09-30 |
2006-12-22 |
Neurosearch As |
1,4-diazabicycloalkane derivatives, their preparation and use in treatment of disorders responsive to modulation of cholmergic and/or monoamine receptors
|
|
US8014953B2
(en)
|
2003-08-08 |
2011-09-06 |
The Regents Of The University Of California |
RNA surveillance among curated proteins
|
|
US7399765B2
(en)
|
2003-09-19 |
2008-07-15 |
Abbott Laboratories |
Substituted diazabicycloalkane derivatives
|
|
US7160876B2
(en)
|
2003-12-22 |
2007-01-09 |
Abbott Laboratories |
Fused bicycloheterocycle substituted quinuclidine derivatives
|
|
US7309699B2
(en)
|
2003-12-22 |
2007-12-18 |
Abbott Laboratories |
3-Quinuclidinyl amino-substituted biaryl derivatives
|
|
US7655657B2
(en)
|
2003-12-22 |
2010-02-02 |
Abbott Laboratories |
Fused bicycloheterocycle substituted quinuclidine derivatives
|
|
US7309487B2
(en)
|
2004-02-09 |
2007-12-18 |
George Inana |
Methods and compositions for detecting and treating retinal diseases
|
|
AR049401A1
(es)
|
2004-06-18 |
2006-07-26 |
Novartis Ag |
Aza-biciclononanos
|
|
GB0415746D0
(en)
|
2004-07-14 |
2004-08-18 |
Novartis Ag |
Organic compounds
|
|
JP5635727B2
(ja)
|
2004-10-07 |
2014-12-03 |
メルク・シャープ・アンド・ドーム・コーポレーションＭｅｒｃｋ Ｓｈａｒｐ ＆ Ｄｏｈｍｅ Ｃｏｒｐ． |
チアゾリルｍｇｌｕｒ５アンタゴニスト及びそれらの使用のための方法
|
|
CA2583217C
(en)
|
2004-10-18 |
2011-05-31 |
Amgen Inc. |
1,3,4-thiadiazole compounds as protein kinase inhibitors
|
|
US7838657B2
(en)
|
2004-12-03 |
2010-11-23 |
University Of Massachusetts |
Spinal muscular atrophy (SMA) treatment via targeting of SMN2 splice site inhibitory sequences
|
|
CN101146796A
(zh)
|
2005-01-26 |
2008-03-19 |
先灵公司 |
作为蛋白激酶抑制剂用于治疗癌症的3-(吲唑-5-基)-(1,2,4)三嗪衍生物及相关化合物
|
|
TW200716594A
(en)
|
2005-04-18 |
2007-05-01 |
Neurogen Corp |
Substituted heteroaryl CB1 antagonists
|
|
US7598052B2
(en)
|
2005-10-11 |
2009-10-06 |
The Regents Of The University Of Michigan |
Expression profile of thyroid cancer
|
|
US8603457B2
(en)
|
2005-12-02 |
2013-12-10 |
University Of Rochester |
Nonsense suppression and genetic codon alteration by targeted modification
|
|
US7834178B2
(en)
|
2006-03-01 |
2010-11-16 |
Bristol-Myers Squibb Company |
Triazine 11-beta hydroxysteroid dehydrogenase type 1 inhibitors
|
|
CN102516241B
(zh)
*
|
2006-05-19 |
2015-07-29 |
艾伯维巴哈马有限公司 |
Cns活性的稠合的双环杂环取代的氮杂双环烷烃衍生物
|
|
ZA200807756B
(en)
|
2006-05-30 |
2009-11-25 |
Neurosearch As |
Novel 1,4-diaza-bicyclo[3.2.2] nonyl oxadiazolyl derivatives and their medical use
|
|
US8314119B2
(en)
|
2006-11-06 |
2012-11-20 |
Abbvie Inc. |
Azaadamantane derivatives and methods of use
|
|
US8343941B2
(en)
|
2007-03-30 |
2013-01-01 |
Rutgers, The State University Of New Jersey |
Compositions and methods for gene silencing
|
|
US8283116B1
(en)
|
2007-06-22 |
2012-10-09 |
Ptc Therapeutics, Inc. |
Methods of screening for compounds for treating spinal muscular atrophy using SMN mRNA translation regulation
|
|
DE102007032507A1
(de)
*
|
2007-07-12 |
2009-04-02 |
Merck Patent Gmbh |
Pyridazinonderivate
|
|
CN101896186A
(zh)
|
2007-10-26 |
2010-11-24 |
莱顿教学医院 |
对抗肌肉病症的方式和方法
|
|
RU2010125121A
(ru)
|
2007-11-21 |
2011-12-27 |
Эббот Лэборетриз (Us) |
Биарилзамещенные производные азабициклических алканов
|
|
US8437067B2
(en)
|
2008-03-18 |
2013-05-07 |
Konica Minolta Holdings, Inc. |
Electrochemical display element
|
|
WO2009151546A2
(en)
|
2008-05-27 |
2009-12-17 |
Ptc Therapeutics, Inc. |
Methods for treating spinal muscular atrophy
|
|
US8133724B2
(en)
|
2008-09-17 |
2012-03-13 |
University Of Maryland, Baltimore |
Human androgen receptor alternative splice variants as biomarkers and therapeutic targets
|
|
WO2010075376A2
(en)
|
2008-12-23 |
2010-07-01 |
Abbott Laboratories |
Anti-viral compounds
|
|
WO2010107733A2
(en)
|
2009-03-16 |
2010-09-23 |
Curna, Inc. |
Treatment of nuclear factor (erythroid-derived 2)-like 2 (nrf2) related diseases by inhibition of natural antisense transcript to nrf2
|
|
US20120149756A1
(en)
|
2009-04-10 |
2012-06-14 |
Associatin Institut de Myologie |
Tricyclo-dna antisense oligonucleotides, compositions, and methods for the treatment of disease
|
|
DK3449926T3
(da)
|
2009-06-17 |
2019-11-11 |
Biogen Ma Inc |
Sammensætninger og fremgangsmåder til modulering af smn2-splejsning hos et individ
|
|
TWI558398B
(zh)
|
2009-09-22 |
2016-11-21 |
諾華公司 |
菸鹼乙醯膽鹼受體α７活化劑之用途
|
|
EP2305679A1
(en)
|
2009-09-28 |
2011-04-06 |
GenKyoTex SA |
Pyrazoline dione derivatives as nadph oxidase inhibitors
|
|
AR079724A1
(es)
*
|
2010-01-20 |
2012-02-15 |
Abbott Lab |
Metodos para el tratamiento del dolor
|
|
DK2531492T3
(en)
|
2010-02-05 |
2016-07-04 |
Heptares Therapeutics Ltd |
1,2,4-triazin-4-amine derivatives
|
|
AR081626A1
(es)
|
2010-04-23 |
2012-10-10 |
Cytokinetics Inc |
Compuestos amino-piridazinicos, composiciones farmaceuticas que los contienen y uso de los mismos para tratar trastornos musculares cardiacos y esqueleticos
|
|
US9133123B2
(en)
|
2010-04-23 |
2015-09-15 |
Cytokinetics, Inc. |
Certain amino-pyridines and amino-triazines, compositions thereof, and methods for their use
|
|
AR081331A1
(es)
|
2010-04-23 |
2012-08-08 |
Cytokinetics Inc |
Amino- pirimidinas composiciones de las mismas y metodos para el uso de los mismos
|
|
US8802642B2
(en)
|
2010-04-28 |
2014-08-12 |
Iowa State University Research Foundation, Inc. |
Spinal muscular atrophy treatment via targeting SMN2 catalytic core
|
|
WO2011163636A2
(en)
|
2010-06-24 |
2011-12-29 |
The Regents Of The University Of California |
Compounds and uses thereof in modulating levels of various amyloid beta peptide alloforms
|
|
KR101764952B1
(ko)
|
2010-07-29 |
2017-08-03 |
리겔 파마슈티칼스, 인크. |
Ａｍｐｋ-활성화 헤테로시클릭 화합물 및 그의 사용 방법
|
|
EP2686021B1
(en)
|
2011-03-14 |
2018-08-15 |
NSE Products, Inc. |
Oral formulations for promoting cellular purification
|
|
US9464065B2
(en)
|
2011-03-24 |
2016-10-11 |
The Scripps Research Institute |
Compounds and methods for inducing chondrogenesis
|
|
WO2013019938A1
(en)
|
2011-08-02 |
2013-02-07 |
The Brigham And Women's Hospital, Inc. |
Pyridazine derivatives as eaat2 activators
|
|
EP2771069A4
(en)
|
2011-10-27 |
2015-08-26 |
Mayo Foundation |
INHIBITION OF POLYPEPTIDES FROM 6-G PROTEIN-COUPLED RECEPTOR RECEPTORS
|
|
CA2861609C
(en)
|
2011-12-30 |
2021-02-16 |
Ptc Therapeutics, Inc. |
Compounds for treating spinal muscular atrophy
|
|
US9399649B2
(en)
|
2012-01-26 |
2016-07-26 |
Ptc Therapeutics, Inc. |
Compounds for treating spinal muscular atrophy
|
|
WO2013117693A1
(en)
|
2012-02-10 |
2013-08-15 |
Glaxosmithkline Intellectual Property Development Limited |
Pde4 inhibitor for treating huntington's disease
|
|
PE20142364A1
(es)
|
2012-02-10 |
2015-01-10 |
Hoffmann La Roche |
Compuestos para tratar atrofia muscular espinal
|
|
KR102099997B1
(ko)
|
2012-03-01 |
2020-04-13 |
피티씨 테라퓨틱스, 인크. |
척수성 근위축증을 치료하기 위한 화합물
|
|
EA028382B1
(ru)
|
2012-03-23 |
2017-11-30 |
ПиТиСи ТЕРАПЬЮТИКС, ИНК. |
Соединения для лечения спинальной мышечной атрофии
|
|
US8729263B2
(en)
|
2012-08-13 |
2014-05-20 |
Novartis Ag |
1,4-disubstituted pyridazine analogs there of and methods for treating SMN-deficiency-related conditions
|
|
AU2013204200B2
(en)
|
2012-10-11 |
2016-10-20 |
Brandeis University |
Treatment of amyotrophic lateral sclerosis
|
|
ES2762326T5
(es)
|
2012-10-15 |
2023-04-27 |
Ionis Pharmaceuticals Inc |
Métodos para modular la expresión de C9ORF72
|
|
WO2014111751A1
(en)
*
|
2013-01-15 |
2014-07-24 |
Novartis Ag |
Use of alpha 7 nicotinic receptor agonists for the treatment of narcolepsy
|
|
BR112015016992A8
(pt)
*
|
2013-01-15 |
2018-01-23 |
Novartis Ag |
uso de agonistas do receptor alfa 7 nicotínico de acetilcolina
|
|
BR112015016995B8
(pt)
*
|
2013-01-15 |
2022-07-26 |
Novartis Ag |
Uso de agonistas do receptor alfa 7 nicotínico de acetilcolina
|
|
ITMI20130063A1
(it)
*
|
2013-01-17 |
2014-07-18 |
Valier Alberto |
Dispositivo manuale per la raccolta dal suolo di frutti o altri oggetti
|
|
US9040712B2
(en)
|
2013-01-23 |
2015-05-26 |
Novartis Ag |
Thiadiazole analogs thereof and methods for treating SMN-deficiency-related-conditions
|
|
WO2014209841A2
(en)
|
2013-06-25 |
2014-12-31 |
F. Hoffmann-La Roche Ag |
Compounds for treating spinal muscular atrophy
|
|
EA030631B1
(ru)
|
2013-07-31 |
2018-09-28 |
Новартис Аг |
1,4-дизамещенные аналоги пиридазинхинолина и способы лечения состояний, связанных с smn-дефицитом
|
|
CA2915764A1
(en)
|
2013-08-19 |
2015-02-26 |
F. Hoffmann-La Roche Ag |
Screening method
|
|
WO2015031036A1
(en)
|
2013-08-26 |
2015-03-05 |
Purdue Pharma L.P. |
Azaspiro[4.5] decane derivatives and use thereof
|
|
US9982260B2
(en)
|
2013-09-30 |
2018-05-29 |
The Regents Of The University Of California |
Identification of structurally similar small molecules that enhance therapeutic exon skipping
|
|
US11162096B2
(en)
|
2013-10-14 |
2021-11-02 |
Ionis Pharmaceuticals, Inc |
Methods for modulating expression of C9ORF72 antisense transcript
|
|
EP3116858B1
(en)
|
2014-03-14 |
2020-11-11 |
RaQualia Pharma Inc. |
Azaspiro derivatives as trpm8 antagonists
|
|
US10006027B2
(en)
|
2014-03-19 |
2018-06-26 |
Ionis Pharmaceuticals, Inc. |
Methods for modulating Ataxin 2 expression
|
|
AU2015272127A1
(en)
|
2014-06-10 |
2017-01-19 |
Erasmus University Medical Center Rotterdam |
Methods for characterizing alternatively or aberrantly spliced mRNA isoforms
|
|
GB201410693D0
(en)
|
2014-06-16 |
2014-07-30 |
Univ Southampton |
Splicing modulation
|
|
US20170355956A1
(en)
|
2014-09-04 |
2017-12-14 |
Rutgers, The State University Of New Jersey |
Compositions for increasing survival of motor neuron protein (smn) levels in target cells and methods of use thereof for the treatment of spinal muscular atrophy
|
|
WO2016064895A1
(en)
|
2014-10-20 |
2016-04-28 |
The Brigham And Women's Hospital, Inc. |
Targeting apolipoprotein e (apoe) in neurologic disease
|
|
US10053697B1
(en)
|
2015-01-09 |
2018-08-21 |
The Board Of Trustees Of The Leland Stanford Junior University |
Programmable alternative splicing devices and uses thereof
|
|
BR112017015273A2
(pt)
|
2015-01-20 |
2018-01-09 |
Merial Inc. |
compostos e composições antihelmínticos e método de utilizações dos mesmos
|
|
EP3053577A1
(en)
|
2015-02-09 |
2016-08-10 |
F. Hoffmann-La Roche AG |
Compounds for the treatment of cancer
|
|
WO2016128343A1
(en)
|
2015-02-09 |
2016-08-18 |
F. Hoffmann-La Roche Ag |
Compounds for the treatment of cancer
|
|
EP4249472A3
(en)
*
|
2015-05-30 |
2023-12-13 |
PTC Therapeutics, Inc. |
Methods for modulating rna splicing
|
|
SG10201912699RA
(en)
|
2015-07-20 |
2020-02-27 |
Genzyme Corp |
Colony stimulating factor-1 receptor (csf-1r) inhibitors
|
|
WO2017041036A1
(en)
|
2015-09-02 |
2017-03-09 |
Pathways Bioscience, Llc |
Compositions and methods for treatment or prevention of oral mucositis
|
|
ES2814251T3
(es)
|
2015-09-24 |
2021-03-26 |
Glaxosmithkline Ip No 2 Ltd |
Moduladores de la indolamina 2,3-dioxigenasa
|
|
US11413278B2
(en)
|
2015-10-08 |
2022-08-16 |
The Regents Of The University Of California |
Compounds and methods for promoting stress resistance
|
|
US10196639B2
(en)
|
2015-10-09 |
2019-02-05 |
University Of Southampton |
Modulation of gene expression and screening for deregulated protein expression
|
|
EP3183347A4
(en)
*
|
2015-10-17 |
2018-04-18 |
Lifesplice Pharma LLC |
Splice modulating oligonucleotides and methods of use thereof
|
|
WO2017080967A1
(en)
|
2015-11-12 |
2017-05-18 |
F. Hoffmann-La Roche Ag |
Compositions for treating spinal muscular atrophy
|
|
US20180344680A1
(en)
|
2015-12-08 |
2018-12-06 |
The Arizona Board Of Regents On Behalf Of The University Of Arizona |
Compositions and methods for treatment, amelioration, and prevention of diabetes-related skin ulcers
|
|
IL281633B
(en)
|
2015-12-10 |
2022-07-01 |
Ptc Therapeutics Inc |
Methods for treating Huntington's disease
|
|
US11096956B2
(en)
|
2015-12-14 |
2021-08-24 |
Stoke Therapeutics, Inc. |
Antisense oligomers and uses thereof
|
|
US11135221B2
(en)
|
2015-12-23 |
2021-10-05 |
Moonshot Pharma Llc |
Methods for inducing an immune response
|
|
AU2017207991A1
(en)
|
2016-01-15 |
2018-08-02 |
Ohio State University |
Pyridazine derivatives as EAAT2 activators
|
|
SG11201806544XA
(en)
|
2016-02-01 |
2018-08-30 |
Arrakis Therapeutics Inc |
Compounds and methods of treating rna-mediated diseases
|
|
CA3015345A1
(en)
|
2016-02-23 |
2017-08-31 |
Indiana University Research & Technology Corporation |
Combination therapies for treatment of spinal muscular atrophy
|
|
US11674952B2
(en)
|
2016-02-24 |
2023-06-13 |
The Rockefeller University |
Embryonic cell-based therapeutic candidate screening systems, models for Huntington's Disease and uses thereof
|
|
US11066456B2
(en)
|
2016-02-25 |
2021-07-20 |
Washington University |
Compositions comprising TREM2 and methods of use thereof
|
|
US20170268066A1
(en)
|
2016-03-15 |
2017-09-21 |
Chalmers Ventures Ab |
Cancer biomarkers
|
|
CA3019240A1
(en)
|
2016-03-29 |
2017-10-05 |
Merck Patent Gmbh |
N1-(3,3,3-trifluoro-2-hydroxy-2-methylpropionyl)-piperidine derivatives as inhibitors of pyruvate dehydrogenase kinase
|
|
CA3019847A1
(en)
|
2016-04-04 |
2017-10-12 |
University Of Florida Research Foundation, Incorporated |
Manipulation of eif3 to modulate repeat associated non-atg (ran) translation
|
|
US10577360B2
(en)
|
2016-04-12 |
2020-03-03 |
Esteve Pharmaceuticals, S.A. |
Arylamide derivatives having multimodal activity against pain
|
|
KR20210082548A
(ko)
|
2016-06-13 |
2021-07-05 |
스칼러 락, 인크. |
미오스타틴 억제제의 용도 및 조합 요법
|
|
MX2018016038A
(es)
*
|
2016-07-01 |
2019-05-13 |
Arrakis Therapeutics Inc |
Compuestos y metodos para modular la funcion del acido ribonucleico (arn).
|
|
EP3544435A4
(en)
|
2016-11-28 |
2020-11-04 |
PTC Therapeutics, Inc. |
RNA SPLICE MODULATION PROCESSES
|
|
JP7129095B2
(ja)
|
2017-02-20 |
2022-09-01 |
国立大学法人京都大学 |
スプライシング異常に起因する遺伝性疾病のための医薬組成物及び治療方法
|
|
EP3628055A4
(en)
|
2017-05-01 |
2021-06-09 |
Thomas Jefferson University |
SYSTEM LEVEL ANALYSIS OF CANCER GENOME ATLAS 32 CANCERS (TCGA) REVEALING PATTERNS OF RNAT FRAGMENTATION DEPENDING ON DISEASE AND HIGHLY SELECTIVE ASSOCIATIONS WITH RNA MESSENGER AND REPEAT ELEMENTS
|
|
CN111372611A
(zh)
*
|
2017-06-14 |
2020-07-03 |
Ptc医疗公司 |
修饰rna剪接的方法
|
|
CA3067591A1
(en)
|
2017-06-28 |
2019-01-03 |
Ptc Therapeutics, Inc. |
Methods for treating huntington's disease
|
|
US11395822B2
(en)
|
2017-06-28 |
2022-07-26 |
Ptc Therapeutics, Inc. |
Methods for treating Huntington's disease
|
|
CN111499615B
(zh)
*
|
2017-08-04 |
2024-02-02 |
斯基霍克疗法公司 |
用于调节剪接的方法和组合物
|
|
EP3686196B1
(en)
|
2017-09-20 |
2024-06-12 |
Hangzhou Innogate Pharma Co., Ltd. |
Polycyclic compound acting as ido inhibitor and/or ido-hdac dual inhibitor
|
|
WO2019075265A1
(en)
|
2017-10-12 |
2019-04-18 |
Revolution Medicines, Inc. |
PYRIDINE, PYRAZINE AND TRIAZINE COMPOUNDS AS ALLOSTERIC INHIBITORS OF SHP2
|
|
US20190167815A1
(en)
|
2017-10-24 |
2019-06-06 |
Sangamo Therapeutics, Inc. |
Methods and compositions for the treatment of rare diseases
|
|
EP3479845A1
(en)
|
2017-11-06 |
2019-05-08 |
Stalicla S.A. |
Challenge test for diagnosing subtype of autism spectrum disease
|
|
WO2019094694A1
(en)
|
2017-11-10 |
2019-05-16 |
University Of Massachusetts |
Compositions and methods for the treatment of expanded repeat-associated disorders
|
|
CA3094703A1
(en)
|
2018-03-27 |
2019-10-03 |
Ptc Therapeutics, Inc. |
Compounds for treating huntington's disease
|
|
CN112272666A
(zh)
|
2018-04-10 |
2021-01-26 |
斯基霍克疗法公司 |
用于治疗癌症的化合物
|
|
MX2020014116A
(es)
|
2018-06-27 |
2021-06-15 |
Reborna Biosciences Inc |
Agente profilactico o terapeutico para atrofia muscular espinal.
|
|
US11685746B2
(en)
|
2018-06-27 |
2023-06-27 |
Ptc Therapeutics, Inc. |
Heteroaryl compounds for treating Huntington's disease
|
|
WO2020005873A1
(en)
|
2018-06-27 |
2020-01-02 |
Ptc Therapeutics, Inc. |
Heterocyclic and heteroaryl compounds for treating huntington's disease
|
|
BR112020026534A2
(pt)
|
2018-06-27 |
2021-03-23 |
Ptc Therapeutics, Inc. |
Compostos de heteroarila para o tratamento da doença de huntington
|
|
US11987568B2
(en)
|
2018-08-03 |
2024-05-21 |
H. Lee Moffitt Cancer Center And Research Institute, Inc. |
Allosteric inhibitor of WEE1 kinase
|
|
TW202028183A
(zh)
|
2018-10-10 |
2020-08-01 |
大陸商江蘇豪森藥業集團有限公司 |
含氮雜芳類衍生物調節劑、其製備方法和應用
|
|
US11129829B2
(en)
*
|
2019-06-17 |
2021-09-28 |
Skyhawk Therapeutics, Inc. |
Methods for modulating splicing
|
|
US20230142338A1
(en)
|
2020-02-28 |
2023-05-11 |
Remix Therapeutics Inc. |
Thiophenyl derivatives useful for modulating nucleic acid splicing
|
|
WO2021174167A1
(en)
|
2020-02-28 |
2021-09-02 |
Remix Therapeutics Inc. |
Compounds and methods for modulating splicing
|
|
CA3169667A1
(en)
|
2020-02-28 |
2021-09-02 |
Dominic Reynolds |
Pyridazine derivatives for modulating nucleic acid splicing
|
|
AU2021228767A1
(en)
|
2020-02-28 |
2022-09-29 |
Remix Therapeutics Inc. |
Heterocyclic amides and their use for modulating splicing
|
|
KR20220167298A
(ko)
|
2020-04-08 |
2022-12-20 |
레믹스 테라퓨틱스 인크. |
스플라이싱을 조절하기 위한 화합물 및 방법
|
|
JP2023520925A
(ja)
|
2020-04-08 |
2023-05-22 |
リミックス セラピューティクス インコーポレイテッド |
スプライシングを調節するための化合物及び方法
|
